


QUALITY



SAFETY



INNOVATION



**Interim Report
January to June 2013**

Key Group Figures

		04/01 - 06/30/2013	04/01 - 06/30/2012	01/01 - 06/30/2013	01/01 - 06/30/2012
Stem Cell Preparations					
Umbilical cord blood storages	Number	1,956	1,986	3,570	3,718
Profit / Loss					
Revenues	EUR k	3,332	3,478	6,502	6,626
Gross profit	EUR k	1,798	2,155	3,680	4,081
EBITDA	EUR k	556	54	898	27
EBIT	EUR k	252	-189	308	-476
Period result	EUR k	88	-165	68	-375
Balance Sheet / Cash Flow				06/30/2013	06/30/2012
Total assets	EUR k			35,039	34,352
Equity	EUR k			20,562	19,634
Equity ratio	%			58.7	57.2
Liquid funds	EUR k			2,625	2,635
Capital expenditures*	EUR k	344	349	514	517
Depreciation*	EUR k	304	243	590	503
Cash flow from operating activities	EUR k	484	480	651	697
Employees					
Employees (as of 30 June)	Number			99	115
Personnel expenditures	EUR k			2,235	2,580

*Information for tangible and intangible assets

Contents

To our shareholders	2
Letter from the Management Board	2
Vita 34 AG Stock	4
Group Interim Report	5
Economic Report	5
Business Activity	5
Market Environment	6
Overview of the First Half-Year 2013	7
Revenue and Profit Situation	8
Financial Situation	9
Assets	9
Subsequent Report	11
Risk and Opportunity Report	11
Outlook	11
Condensed Consolidated Interim Financial Statements	13
Condensed Consolidated Statement of Income	13
Condensed Consolidated Statement of Financial Position	14
Condensed Consolidated Statement of Changes in Group Equity	16
Condensed Consolidated Statement of Cash flows	18
Notes on the Condensed Consolidated Interim Financial Statement	19
Declaration of the Legal Representatives	23
Credits	24

Letter from the Management Board

Dear Shareholders,

We have been successful in significantly increasing our central key financial figure, earnings before interest, taxes, depreciation and amortization (EBITDA), from EUR 27k in the first half-year of 2012 to EUR 898k. Whereas earnings before interest and taxes (EBIT) was still in the negative range after the first half-year of 2012 at EUR -476k, as of the closing date June 30, 2013 it was EUR 308k. The savings measures initiated in 2012 for increasing profitability have demonstrated an effect. The group result was EUR 68k, following EUR -375k in the prior year's reference period. After 2010, we have thus returned to a profitable range.

In the reporting period we posted revenues of EUR 6.5 million, which were level with the prior year's level of EUR 6.6 million. The ongoing difficult situation in Spain is reflected in declining storages of umbilical cord blood. The storage figures are stagnant in Germany, as well: In the first half of 2013 a total of 3,570 stem cell preparations were stored, which is some 4% less than the prior year's period, which had 3,718.

We are faced with great challenges in sustainably improving the economic situation of Vita 34 AG. We are, however, convinced that we will overcome these challenges in our good market position and thanks to the measures we have initiated.

Currently, we have stored the umbilical cord blood of over 95,000 children, and we have capacity for up to 350,000 units. Thus, we are the undisputed leading stem cell bank in the German-speaking countries, and have created the basis for future growth. Since the observance of the highest quality standards in the cryo-preservation of stem cells is our top priority, we are the only private stem cell bank in Germany that can demonstrate tangible medical applications of the umbilical cord blood stored for the patient's own use. As the only German private stem cell bank we have permits for dispensing umbilical cord blood preparations for therapeutic use, both for the child's own use, or that of siblings, within the family or as a donation to others. These aspects are the reasons for our dominant market share amongst private umbilical cord blood and stem cell banks in Germany.

In the first half-year of 2013 we have expanded our foreign activities and continuously increased contact with experts in research, medical practice and our customers, the expecting parents. We have come one decisive step closer to an expansion of our product range with a permit for the storage of umbilical cord blood tissue. Overall, we consider ourselves to be in a good position for crafting the development of Vita 34 in positive manner on an ongoing basis.

At this juncture, we would like to thank our shareholders for the trust extended and hope that you will accompany us in our further corporate development

Leipzig, July 2013



Dr. André Gerth
CEO



Jörg Ulbrich
CFO




Dr. André Gerth – CEO

Jörg Ulbrich – CFO

Vita 34 AG Stock

Stock Price Development




The Vita 34 AG stock began the year 2013 with a price of EUR 3.05, and it reached its quarterly and half-year high of EUR 3.15 on January 15. Within the context of a downward trend the stock price experienced its low of EUR 2.86 within the second quarter of 2013 on April 10, 2013, however, it subsequently recovered and closed at the same level as the beginning of the year of EUR 3.05 on June 28, 2013 after nearly two months of lateral movement. This is equivalent to market capitalization of EUR 9.2 million.

Key Data

Ticker symbol/ Reuters symbol	V3V/ V3VGn.DE
Securities number/ ISIN	A0BL84/ DE000A0BL849
Initial quotation	27 March 2007
Market segment	Prime Standard
Index	CDAX, Prime All Share, Technology All Share, DAX- subsector Biotechnology, DAXsector Pharma & Healthcare
Opening/Closing price	EUR 3.05/EUR 3.05
High/Low	EUR 3.15/EUR 2.80
Number of shares	3,026,500
Free float as of June 30, 2013	47.5 %
Market capitalization as of June 30, 2013	EUR 9.2 million
Designated Sponsor	Close Brothers Seydler Bank

Shareholder Structure



* This only includes founders/management with a stake of 5% or above.

Financial Calendar 2013

24 October 2013	Publishing of the 9-month report
-----------------	-------------------------------------

Group Interim Report

Economic Report

Business Activity

Vita 34 was the first private umbilical cord blood bank in Europe, and in the 16 years since its founding has developed into a specialist for biobanking. The company is active in two business segments: The storage of umbilical cord blood and biotechnology.

The core business of Vita 34 is the cryo-preservation of umbilical cord blood. Here Vita 34 covers the entire value chain from collection logistics, to preparation, to the permanent storage of the umbilical cord blood at roughly -190°C. Here, cells are preserved alive at this temperature, and can be used if needed in the context of medical treatment.


With currently more than 95,000 umbilical cord blood storages, Vita 34 is the market leader in the German-speaking countries. Across Europe, 24 preparations from the cryo-tanks at Vita 34 have been used for 56 therapeutic applications with umbilical cord blood, reported to Cord Blood Europe. This outstanding application rate underscores the high level of quality of our storages.

As the only private stem cell bank, Vita 34 has permits from the German Federal Institute for Vaccines and Biomedical Pharmaceuticals (Paul-Ehrlich-Institute) for dispensing umbilical cord blood preparations for the therapeutic use in hematological/oncological diseases for siblings, and to help other people in the case of disease in the form of a donation.

The offering of Vita 34 is targeted towards expecting parents who wish to have vital stem cells, free of environmental stresses, preserved for their children immediately after birth as a provision. Thus, they give their children the opportunity to benefit from discoveries in stem cell research in the case of illness.

Vita 34 has continuously expanded its activities in the international market in the past years. With subsidiaries in Spain, Austria and Slovakia, as well as sales and cooperative venture partners on the European and global markets, Vita 34 is also increasingly active outside of Germany. Vita 34 has a network of some 10,000 OB/GYNs and has entered into agreements with about 95% of the approx. 800 birthing clinics in Germany for the collection of umbilical cord blood.

Group structure



International Presence



In the fields of biotechnology, Vita 34 is active in consulting on environment projects, as well as pharmaceutical and biotechnological development. Vita 34 has expanded into this business segment with the takeover and merger of BioPlanta GmbH, a project management company in the field of biotechnology. The Vita 34 core business also profits from this takeover: Apart from an international network, Vita 34 has gained decisive competencies in project management.

Market Environment

During the first six month of 2013, a gradual recovery of the world economy was observable according to the Kiel Institute of the World Economy (IfW). In all, IfW expects a global growth rate of 3.2% in the further course of 2013, and 3.8% in the coming year 2014.¹

The European region is still affected by a recession, which the prognosis of IfW is based on, according to which GDP in 2013 will decrease by 0.6%. On the other hand, an increase of 0.8% is expected for the year 2014.²

The most important markets for Vita 34 are Germany, Spain and Italy. The economic output of Spain sank again by 0.5% in the first quarter of 2013 as compared with the fourth quarter of 2012 according to information from the national statistics institute INE. In addition, the expenditures by private households were 0.4% lower than the prior quarter.³

The economy in Germany stabilized in the first half-year of 2013. Although the increase in GDP according to the IfW with a current annual rate of 0.3% is lower than expected, the economic barometer of the German Institute for Economic Research (DIW Berlin) has indicated an increase in growth of some 0.5% for the second quarter.⁴

The decision to store umbilical cord blood is, among other things, dependent on purchasing power, as well as the income of the populace. For the year 2013 GfK (Gesellschaft für Konsumforschung) a consumer research company has forecast an increase in purchasing power of some 2.9% as compared with the prior year 2012.⁵ The

¹ Institute for the World Economy, World Economy in Summer 2013, June 19, 2013 | ² Institute for the World Economy, "World Economy Only Gaining Momentum Gradually," Media information dated June 20, 2013 | ³ <http://www.welt.de>, "Spain's economy shrinks for the seventh time", May 30, 2013 | ⁴ Institute for the World Economy, The German Economy in Summer 2013, June 19, 2013 | ⁵ Gesellschaft für Konsumforschung [GfK], "Purchasing Power 2013: Germans have EUR 554 More", Press release, December 12, 2012

German Federal Office for Statistics expects an increase in gross annual wages of some 9% between the years 2012 and 2016.⁶ The unemployment rate, which averaged 7.1% in the course of 2013 to date, remains at a relatively stable level.⁷

An additional indicator for the Vita 34 business environment is developing in a positive manner: According to a current study by the Max Planck Institute, the “ultimate birth rate” (cohort fertility) in 26 of the 37 countries studied will trend upward again.⁸ The variable is different than the tabulated number of births – current number of children per woman in a specific calendar year – rather the final number of children that woman of a birth year have in their lifetime, which provides a more realistic picture. This number is estimated for women who have not yet reached age 50.

The German Federal Office of Statistics indicated a birth rate of 1.36 children per woman in 2011. By comparison, the cohort fertility in Germany for women who are reaching age 35 in the same calendar year is between 1.54 and 1.57 according to the current study. The trend is upward: For women who have reached age 34 today, the cohort fertility is nearly 1.6 children per woman. The average of all 37 countries studied for women born in 1975 is even 1.77 children. Thus, although in the reporting period Vita 34 was faced with the problem of a currently stagnating birth rate in Germany and a declining birth rate in Spain, in the next few years there are positive market opportunities with regard to the final birth rate.

According to the German Federal Office of Statistics most children in Germany are born to women between the ages of 26 and 35.⁹ In 2011 women were an average of 29.1 years old when their first child was born.¹⁰ Reasons for ever later motherhood include the fact that well-educated women wish to have a solid position in their profession and a stable financial starting point before fulfilling their wish to have children. Thus, women have children most frequently at an age, in which they are also most receptive to the Vita 34 offering, according to our own observations. Here, there is also potential for additional positive business development.

Overview of the First Half-Year 2013

During the first half-year of 2013 Vita 34 worked continuously on strengthening and expanding its leading market position in the Germany speaking countries and internationally.

Expansion of Product Range

In the reporting period, Vita 34 was able to create all of the prerequisites for the planned expansion of the product palette to include “VitaPlusNabelschnur” (VitaPlusCord). This entails the storage of umbilical cord tissue according to Good Manufacturing Practice guidelines (GMP). In May the State Directorate Saxony and the Paul-Ehrlich-Institute conducted an inspection on-site in Leipzig. The inspectors subsequently granted Vita 34 a permit for the processing, cryo-preservation and storage of umbilical cord tissue. Currently, a permit for collecting the umbilical cord for the collection unit according to § 20b German Pharmaceuticals Act is being reviewed. With the expected permit issuance, Vita 34 will be the only private umbilical cord blood bank in Germany that can not only store umbilical cord blood, but also umbilical cord tissue, thus following the international development for the use of mesenchymal stem cells – precursor cells of connective tissue.

International Presence

Vita 34 was able to make a significant mark on the international market in the first half-year 2013. In Q1 2013 already Vita 34 had optimized sales activities in Spain and audited the required quality level of its Chilean partner. In addition, Vita 34 was able to expand its sales cooperation with partner Bio Save d.o.o. to Macedonia and Bosnia-Herzegovina. In Q2 2013 Vita 34 focused especially on opening the market in Vietnam, Brazil and Bulgaria.

In Hanoi, Vietnam, Vita 34 employees were on-site at the National Hospital of Obstetrics in April, in order to train selected clinic personnel in the theoretical principals of the Good Manufacturing Practice Guidelines (GMP), and hygiene regulations, as well as umbilical cord blood preparation. Dr. André Gerth together with Deputy Health Minister Dr. Nguyen Viet Tien signed a cooperation agreement between the hospital and Vita 34.

⁶ <http://de.statista.com> | ⁷ <http://de.statista.com> | ⁸ Myrskylä, Mikko u.a. (Max-Planck-Institute) “New Cohort Fertility Forecasts for the Developed World: Rises, Falls, and Reversals”, March 2013 | ⁹ German Federal Statistical Office, “Of low birth rates and a lack of maternal...”, September 20, 2012

¹⁰ German Federal Ministry for Family Affairs, Senior Citizens, Women and Youth, Family Report 2012

Vita 34 presented its own technologies and services for the preparation and storage of umbilical cord blood and tissue at the international fair for hospital equipment and supplies "HOSPITALAR 2013" in São Paulo, Brazil. During the leading trade fair in the field of healthcare in South America, Vita 34 was able to forge contacts with Brazilian umbilical cord blood banks and hospital chains.

In Bulgaria, Vita 34 is working together with additional cooperation partners. Vita 34 will, as is usual in the case of European cooperative ventures, handle the preparation and storage of the umbilical cord blood in Leipzig.

First Stem Cell Day in Leipzig

Vita 34 held its first Stem Cell Day in Leipzig during the reporting period. Domestic and foreign experts from seven countries built a bridge between research and practical medicine within the scope of the event. Vita 34 was able to strengthen contacts with important multipliers, and expand its own network.

New Campaign "Thanks Mama"

Vita 34 has given its core business, the storage of umbilical cord blood, a face with the current campaign. Children, whose umbilical cord blood is stored at Vita 34, stood before the camera in Leipzig for this. The central message of the "Thanks Mama" campaign honors the forward-looking action of the expecting parents. Umbilical cord blood storage is an important first healthcare provision, a type of biological insurance, with which parents can give their children the chance to profit from discoveries in stem cell research in the case of disease.

Biotechnology Business Segment

Vita 34 merged operatively with BioPlanta GmbH in the first quarter of 2013.

In the reporting period Vita 34 conducted training in Laos and Cambodia on sustainable mining. In particular, the avoidance of environmental impairments such as water, air and soil pollution were of particular relevance, here.

Revenue and Profit Situation

The revenue and profit situation of Vita 34 in the reporting period was characterized by the continued tense economic situation in Spain and the resulting decrease in storages of umbilical cord blood in this market. In Germany, the home market, the number of new storages of stem cell preparations also declined. Whereas 3,718 umbilical cord blood preparations were stored at Vita 34 in the prior year's period, the number of storages in the reporting period decreased by some 4% to 3,570.

This development in new storages was reflected accordingly in the total revenues for the first half-year 2013. In a comparison with the prior year revenues decreased by 1.9% from EUR 6.6 million to EUR 6.5 million in the reporting period 2013. Here, Vita 34 posted revenues of EUR 3.3 million in Q2 2013, following EUR 3.5 million in the prior year's quarter. According to business segment in the first half-year 2013 some EUR 6.2 million was attributable to the Storage of Umbilical Cord Blood segment and some EUR 0.3 million to the Biotechnology business segment.

In Q2 2013 the cost of sales was EUR 1.5 million, following EUR 1.3 million in the 2012 reference period. Due to the capacity-related move to space in the "BioCube" in Leipzig and the increased costs for space, as well as the cost of the Biotechnology business segment, the cost of sales in all in the first half-year 2013 increased by 10.9% to EUR 2.8 million, following EUR 2.5 million in the prior year's period. The Biotechnology business segment was only added and the costs posted in the second half-year 2012.

The gross profit from sales in Q2 2013 was EUR 1.8 million; this is equivalent to a gross margin of some 54% as compared with some 62% in the corresponding period in the prior year 2012. In the first half-year 2013 the gross profit was reduced to a total of EUR 3.7 million, following EUR 4.1 million in the 2012 reporting period.

The Other Operating Income increased as compared to the first half-year 2012 from EUR 228k to EUR 402k in the reporting period 2013. This increase is based on increased public income from research and development.

To increase profitability, in fiscal year 2012 cost reduction measures were introduced and this was continued in the reporting period. The selling expenses dropped as a consequence in Q2 2013 to some EUR 1.1 million from EUR 1.6 million in the reference period the prior year. In all, the selling expenses decreased significantly in the first half-year 2013 to EUR 2.4 million from EUR 3.2 million in the prior year's period.

The central, key financial figure, earnings before interest, taxes, depreciation and amortization (EBITDA), therefore, increased significantly in the first half-year 2013 to EUR 898k, following EUR 27k in the first half-year 2012. After the first half-year 2012 earnings before interest and taxes (EBIT) was still in the negative range at EUR -476k. EBIT also increase clearly and was EUR 308k as of the closing date June 30, 2013.

Income tax expense of EUR 113k was incurred in Q2 2013. In the corresponding period a year before, there was a tax credit of EUR 66k. After negative earnings before tax (EBT) in the amount of EUR -511k in the first half-year 2012, an income tax credit of EUR 136k resulted, and in the reporting period 2013 an income tax expense in the amount of EUR 213k was incurred due to the positive EBT of EUR 281k.

The period result in the first half-year 2013 was EUR 68k, following EUR -375k in the comparable time period in 2012. This results in a profit per share of EUR 0.04 in the reporting period based on an average number of issued shares of 3,026,500, following EUR -0.14 with 2,646,500 shares in the first half-year of 2012. Overall, the period result increased significantly despite a decrease in the storages of umbilical cord blood, and Vita 34 returned to the profit zone after 2010, in particular due to the successful implementation of efficiency increasing measures.

Financial Situation

Based on a period result before income taxes in the amount of EUR 281k in the first half-year of 2013, at EUR 590k the greatest share of non-cash adjustments was for planned depreciation. In the reference period of the prior year 2012, this was EUR 503k with a period result before income tax of EUR -511k. Taking into consideration a decrease in cash of EUR -154k in net current assets, following an increase of EUR 820k in the reference period of the prior

year, the cash flow from operating activities in the first half-year of 2013 was EUR 651k, following EUR 697k in the first half-year 2012.

In the first half-year 2013 Vita 34 invested a total of EUR 514k in intangible assets and plant and equipment, thus this was at the level of the prior year. The cash flow from investment activities in the first half-year 2013 of EUR -503k was also approximately at the prior year's level. Investments in property, plant and equipment mainly pertained to the expansion of storage capacity for umbilical cord blood preparations. In the reporting period EUR 159k was invested for the cryo-tanks needed for storage. The acquisition of intangible assets includes, in particular, payments for custom software development.

Due to the planned redemption of loans, the cash flow from financing activities as of June 30, 2013 was EUR -1.0 million, following EUR -0.6 million in the prior year's period.

Thus, as of June 30, 2013, Vita 34 had cash holdings of EUR 2.6 million.

Assets

On the assets side of the balance sheet, the non-current assets were EUR 28.0 million in the reporting period, and were at a level comparable with the end of fiscal year 2012 when they were EUR 28.4 million. In particular, this contains the goodwill of EUR 13.9 million, which remained unchanged as compared with December 31, 2012. This is comprised of the goodwill of Vita 34 AG, the Spanish subsidiary Secuvita, S.L., and the Biotechnology business segment.

Current assets decreased in the first half-year of 2013 from EUR 7.0 million, following EUR 8.2 million as of December 31, 2012. This development was influenced by the extinguishment of current interest-bearing loans using cash. Accordingly, cash and cash equivalents as of June 30, 2012 decreased to EUR 2.6 million, following EUR 3.5 million as of December 31, 2012.


On the liabilities side of the balance sheet, equity as of the closing date June 30, 2013 was EUR 20.6 million due to slightly increased retained earnings and, thus, slightly over the 2012 year end level of EUR 20.5 million.

The longterm liabilities and deferred income of EUR 10.6 million as of June 30, 2013 were nearly unchanged, following EUR 10.5 million at the end of 2012. Current liabilities without deferred income decreased from EUR 5.6 million at the end of as of December 31, 2012 to EUR 3.9 million as of June 30, 2013. This can be traced to the planned redemption of loans: Current interest bearing loans decreased from EUR 1.8 million at the end of 2012 to EUR 0.7 million as of June 30, 2013.

Deferred income was EUR 9.5 in the reporting period, in the wake of EUR 9.4 million as of December 31, 2012. This contains the storage fees that are collected from customers one time in advance. They are dissolved in linear fashion over the agreed storage period.

Vita 34 continued to have a solid balance sheet structure at the end of the reporting period 2013. With a balance sheet total of EUR 35.0 million the equity ratio as of June 30, 2013 was 58.7%, and thus had increased, following 56% and a balance sheet total of EUR 36.6 million as of December 31, 2012.

Balance Sheet (EUR k)



Subsequent Report

Following the closing of the reporting period, no significant events have occurred that would have had a substantial effect on the picture of the asset, financial and profit situation of the group portrayed by this interim report.

Risk and Opportunity Report

As compared with the opportunities and risks presented in the 2012 annual report, there have been no significant changes in the reporting period. More information on the special risks of Vita 34 AG can be found in the "Internal Controlling and Risk Management System and Risk Report" chapter of the Vita 34 AG annual report of March 28, 2013. This can be downloaded from the Vita 34 website (www.vita34group.de).

Outlook

In the first half-year of 2013, Vita 34 was able to assert itself in a challenging environment. A positive result was earned despite stagnating and declining revenue trends. The cost reduction measures introduced show the desired affect in the reporting period, such that the most important key financial figure (EBITDA) of EUR 898k was significantly higher than in the prior year's period. Thus, Vita 34 trusts that it can achieve the prognosis for fiscal year 2013 contained in the 2012 Annual Report. This prognosis foresees a significant increase in the operative result (EBITDA) to at least EUR 1.0 million.

For the second half-year 2013, Vita 34 is faced in particular with the challenge of stabilizing revenues in the two core markets Germany and Spain. To do this, Vita 34 will intensively pursue corresponding measures, which have already been initiated. Expecting parents are to be made increasingly aware of Vita 34 with the new "Thanks Mama" campaign. With "VitaPlusNabelschnur" (VitaPlusCord) Vita 34 will be the only private umbilical cord blood bank in Germany to offer them an additional product for the storage of umbilical cord blood. It can be assumed that with the extension of the product range new revenue potential will result, which Vita 34 will use for expanding its leading position in the storage of umbilical cord blood and umbilical cords.

On the sales side, Vita 34 will continue to concentrate on entering attractive markets.

Competencies in the fields of research and development as well as biotechnology were gained in the acquisition of BioPlanta in 2012. The resulting synergic effects will be used for the systematic development to be a supplier of cell products for pharmaceutical and therapeutic applications.

The diverse research results in the field of regenerative medicine document the good chances of success for the further development of the company.

Leipzig, July 2013


Dr. André Gerth
CEO


Jörg Ulbrich
CFO

Condensed Consolidated Interim Financial Statements 06/30/2013

Condensed Consolidated Statement of Income

EUR k	Note	04/01- 06/30/2013	04/01- 06/30/2012	01/01- 06/30/2013	01/01- 06/30/2012
Continuing operations					
Revenue		3,332	3,478	6,502	6,626
Cost of sales		-1,534	-1,323	-2,822	-2,545
Gross profit on sales		1,798	2,155	3,680	4,081
Other operating income		234	148	402	228
Marketing and selling expenses		-1,063	-1,622	-2,352	-3,197
Administrative expenses		-660	-704	-1,284	-1,342
Other operating expenses		-57	-166	-138	-246
Net operating profit/loss		252	-189	308	-476
Finance revenue		6	4	62	65
Finance costs		-57	-46	-89	-100
Earnings before taxes		201	-231	281	-511
Income tax expense/income	5	-113	66	-213	136
Period result/Comprehensive income after tax		88	-165	68	-375
Period result/Comprehensive income after tax attributable to					
Owners of the parent		106	-158	106	-359
Non-controlling interests		-18	-7	-38	-16
Earnings per share, basic/diluted (EUR)					
Attributable to ordinary equity holders of the parent				0.04	-0.14

Condensed Consolidated Statement of Financial Position (Assets)

EUR k	Note	06/30/2013	12/31/2012
Non-current assets			
Goodwill		13,942	13,942
Intangible assets		7,178	7,481
Property, plant and equipment		4,763	4,537
Other financial assets		57	74
Deferred tax assets		497	691
Non-current trade receivables		1,350	1,431
Restricted cash		232	288
		28,019	28,444
Current assets			
Inventories		506	633
Trade receivables		2,259	2,665
Other receivables and assets		1,630	1,389
Cash and cash equivalents	4	2,625	3,497
		7,020	8,184
		35,039	36,628

Condensed Consolidated Statement of Financial Position (Equity and Liabilities)

EUR k	Note	06/30/2013	12/31/2012
Equity			
Issued capital		3,027	3,027
Capital reserves		23,950	23,950
Revenue reserves		-6,179	-6,285
Treasury shares		-436	-436
Non-controlling interests		200	238
		20,562	20,494
Non-current liabilities and deferred income			
Interest-bearing loans		347	349
Silent partners' interests		940	940
Provisions		118	172
Deferred grants		969	1,006
Pension provisions		50	50
Deferred income		8,157	8,003
		10,581	10,520
Current liabilities and deferred income			
Trade payables		850	1,168
Provisions		194	349
Income tax liabilities		2	2
Interest-bearing loans		717	1,791
Deferred grants		73	73
Other liabilities		686	881
Deferred income		1,374	1,350
		3,896	5,614
		35,039	36,628

Condensed Consolidated Statement of Changes in Group Equity

TEUR	Equity attributable to the		
	Issued capital	Capital reserves	Revenue reserve
Balance as of 1 January 2012	2,647	23,236	-5,706
Period result			-359
Balance as of 30 June 2013	2,647	23,236	-6,065
Balance as of 1 January 2013	3,027	23,950	-6,285
Period result			106
Balance as of 30 June 2013	3,027	23,950	-6,179

owners of the parent

Total shareholders' equity	Treasury shares at acquisition costs	Non-controlling interests	Total equity
20,177	-436	268	20,009
-359		-16	-375
19,818	-436	252	19,634
20,692	-436	238	20,494
106		-38	68
20,798	-436	200	20,562

Condensed Consolidated Statement of Cash flows

EUR k	Note	01/01- 06/30/2013	01/01- 06/30/2012
Cash flow from operating activities			
Earnings before taxes		281	-511
Adjusted for:			
Amortization and depreciation		590	503
Gains/losses from the disposal of non-current assets		0	17
Other non-cash expenses/income		-14	8
Finance revenue		-62	-65
Finance costs		89	100
Cash flow from ordinary operations:			
+/- Trade receivables and other receivables and assets		263	152
+/- Inventories		127	-127
+/- Trade payables and other Liabilities		-513	15
+/- Provisions		-209	4
+/- Deferred income		178	776
Interest paid		-60	-98
Income taxes paid		-19	-77
Cash flow from operating activities		651	697
Cash flow from investing activities			
Purchase of intangible assets		-142	-144
Purchase of property, plant and equipment		-372	-373
Cash received from the sale of property, plant and equipment		0	8
Interest received		11	14
Cash flow from investing activities		-503	-495
Cash flow from financing activities			
Changes in restricted cash		56	1
Cash received from investment grants		0	97
Changes in loans		-1,076	-691
Cash flow from financing activities		-1,020	-593
Net change in cash and cash equivalents		-872	-391
Cash and cash equivalents at the beginning of the reporting period		3,497	3,026
Cash and cash equivalents at the end of the reporting period (Liquid funds)	4	2,625	2,635

Notes on the Condensed Consolidated Interim Financial Statement

1. Company Information

The parent company, Vita 34 AG (the "Company"), with headquarters in Leipzig (Germany) Deutscher Platz 5a, listed in the commercial register of the District Court of Leipzig under HRB 20339, is a company whose corporate purpose is the storage, the production and the sale of stem cell and blood products for therapy and transplantation, the development, production and sale of medicinal products, as well as conducting projects in the field of biotechnology. Its subsidiaries (together with the Company referred to as the "Group") also operate in the field of cord blood storage.

The group interim financial statements for the period from January 1 until June 30, 2013 were approved for publication by the Management Board on July 25, 2013.

2. Accounting and Valuation Principles

2.1 Basis for the Preparation of the Financial Statements

The preparation of the group interim financial statements for the period from January 1 until June 30, 2013 has been conducted in accordance with IAS 34 "Interim Financial Reporting."

The condensed group interim financial statements do not contain all of the explanations and information prescribed for the annual financial statements and should be read in conjunction with the group financial statements as of December 31, 2012.

2.2 Changes in Accounting Policies

The accounting and valuation methods used to prepare the group interim financial statements correspond with the methods used in the preparation of the group financial statements for the fiscal year as of December 31, 2012.

The group used the following new and revised IFRS standards and interpretations for the first time as of January 1, 2013:

- Changes to IFRS 1: Severe Hyperinflation and Removal of Fixed Dates for First-time Adopters
- Changes to IFRS 1: Government Loans
- Changes to IFRS 7: Financial Instruments: Disclosures
- IFRS 13: Fair Value Measurement
- Revisions to IAS 1: Presentation of Items of Other Comprehensive Income
- Revisions to IAS 12: Recovery of Underlying Assets
- Changes to IAS 19: Employee Benefits
- IFRIC 20, Stripping Costs in the Production Phase of a Surface Mine
- Improvements to the International Financial Reporting Standards, cycle 2009-2011

The standards and interpretations required to be used for the first time starting January 1, 2013 resulted in no significant effects on the interim financial statements of Vita 34 AG.

3. Consolidation Group

The consolidated interim financial statements encompass, apart from the parent company Vita 34 AG, the interim financial statements of the following subsidiaries:

- Novel Pharma, S.L., Madrid, Spain
- Secuvita, S. L., Madrid, Spain

4. Cash and Cash Equivalents

For the purposes of the consolidated statement of cash flows, the cash and cash equivalents consist of the following:

EUR k	06/30/2013	06/30/2012
Cash at banks and in hand	2,625	2,635

5. Income Taxes

The significant components of the income tax expenditures listed in the condensed consolidated income statement consist of the following:

Consolidated Statement of Income	01/01 - 06/30/2013	01/01 - 06/30/2012
EUR k		
Current income tax/expense		
Deferred income tax	19	0
Origination and reversal of temporary differences	7	-39
on unused tax losses	187	-97
Income tax expense income	213	-136

6. Segment Reporting

The group is organized into business units according to products and services for the purpose of corporate taxation, and has the following two reporting business segments:

- The "Storage of Umbilical Cord Blood" segment is active in the field of the storage, production and sale of stem cell and blood products for therapy and transplantation, and the development, production and sale of medicinal products;
- The "Biotechnology" business segment develops biological processes for cell and tissue culture and employs them in the optimization and multiplication of cells and plants. Analyses and services are performed for environmental projects.

The operating profit/loss of the business units is monitored by management separately, in order to make decisions concerning the distribution of resources and to determine the profitability of the units. The development of the segments is evaluated using operating profit. The group financing (including finance income of EUR 62k and finance expense of EUR 89k) as well as taxes on income and profits, are taxed uniformly across the group and are not attributed to the individual segments.

The offset prices between the operative segments are determined in accordance with typical market conditions amongst unrelated third-parties.

The following table contains information on income and segment results of the operating segments of the Group for the period from January 1 to June 30, 2013:

Period from 01/01-06/30/2013					
EUR k	The Storage of umbilical cord blood	Bio- technology	Total	Consoli- dated	Group
Revenue from transactions with external customers	6,246	256	6,502	0	6,502
Revenue from transactions with other segments	0	0	0	0	0
	6,246	256	6,502	0	6,502
EBIT (operating profit)	311	-3	308	0	308
Depreciation	520	70	590	0	590
Segment assets	32,884	2,155	35,039	0	35,039
Segment liabilities	-13,896	-581	-14,477	0	-14,477

In the previous year, the company only had the "Storage of Umbilical Cord Blood" business segment. Therefore, a presentation of the prior year's figures for the comparative period has not been included.

The following table contains information on sales revenues and segment results of the geographic segments of the group for the period from January 1 to June 30, 2013, or 2012:

6.1 Information Concerning Geographic Regions

The geographic segments of the group are determined in accordance with the revenues earned in the geographical areas.

Period from 01/01-06/30/2013					
EUR k	DACH	Spain	Total	Consoli- dated	Group
Income from transactions with external customers	4,873	1,629	6,502	0	6,502
Income from transactions with other segments	314	0	314	-314	0
	5,187	1,629	6,816	-314	6,502
EBIT (operating profit)	570	-262	308	0	308
Depreciation	388	202	590	0	590
Segment assets	25,536	8,174	33,710	1,329	35,039
Segment liabilities	-6,642	-6,506	-13,148	-1,329	-14,477

Period from 01/01-06/30/2012					
EUR k	DACH	Spain	Total	Consoli- dated	Group
Income from transactions with external customers	4,956	1,670	6,626	0	6,626
Income from transactions with other segments	321	0	321	-321	0
	5,277	1,670	6,947	-321	6,626
EBIT (operating profit)	-317	-159	-476	0	-476
Depreciation	303	200	503	0	503
Segment assets	33,709	7,930	41,639	-7,287	34,352
Segment liabilities	-11,174	-10,797	-21,971	7,253	-14,718

7. Information on Relationships to Friends and Family

The following table contains the compensation of persons in key positions in the period from January 1 to June 30, 2013 or 2012:

EUR k	2013	2012
Compensation of key management personnel of the Group:		
Short-term benefits:		
Remuneration of the Supervisory Board	14	13
Management board salaries	174	182

In fiscal year 2013 a GmbH (German limited liability company) with close ties to a Supervisory Board member, provided services to the Group. The cost to the Group for the services rendered was EUR 30k.

All transactions with the close company were executed under terms, as would have been customary with unrelated third parties.

Declaration of the Legal Representatives

We hereby affirm that to the best of our knowledge the consolidated financial statements provide a picture of the asset, financial and profit situation of the Group, which reflects the actual circumstances in accordance with the applicable accounting policies, and that the management report presents the course of business, including the financial results, and the situation of the Company in a manner that corresponds with the actual circumstances, and that the most important opportunities and risks of the foreseeable development of the Group have been described.

Leipzig, July 2013

Management Board of Vita 34 AG



Dr. André Gerth
CEO



Jörg Ulbrich
CFO

Credits

Contact

Vita 34 AG
Deutscher Platz 5
04103 Leipzig
Germany

Telephone: +49 341 48792-40
Fax: +49 341 48792-39
E-Mail: ir@vita34group.de

Copy and Editing

Vita 34 AG, Leipzig
cometis AG, Wiesbaden

Production

The production of the paper is certified in accordance with DIN ISO 9001 and 14001. The cellulose and paper plants of the manufacturer are certified in accordance with FSC Chain of Custody. The wood originated exclusively from controlled and sustainably managed forests.

Forward-looking statements

This Management Report contains statements and forecasts pertaining to the future development of Vita 34 AG. These forecasts are estimates we made based on information that was available at the current time. Actual developments and currently expected results may vary in the event that assumptions that form the basis for the forecasts do not take place, or risk actually occur.

This Interim Report was published in German and English on 25 July 2013 and is available for download on our internet site.

Vita 34 on the Internet: www.vita34group.com

Vita 34 AG

Registered office: Deutscher Platz 5 | 04103 Leipzig | Telephone +49 (0) 341 487 92 40 | Telefax +49 (0) 341 487 92 39

Mailing address: Perlickstraße 5 | 04103 Leipzig

E-Mail ir@vita34group.de | www.vita34group.com | www.facebook.com/vita34

Picture credits: Cover from iStockphoto (18269779)